AR074584A1 - Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables - Google Patents
Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradablesInfo
- Publication number
- AR074584A1 AR074584A1 ARP090104793A ARP090104793A AR074584A1 AR 074584 A1 AR074584 A1 AR 074584A1 AR P090104793 A ARP090104793 A AR P090104793A AR P090104793 A ARP090104793 A AR P090104793A AR 074584 A1 AR074584 A1 AR 074584A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid
- tris
- pharmaceutical formulation
- formula
- formulation according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe un sistema de liberación de un fármaco de fase dual de camptotecina/polímero que es estable tanto en estado líquido como liofilizado. El polímero contiene acetales y/o cetales. Reivindicación 1: Una formulación farmacéutica apropiada para administración endovenosa que comprende un compuesto de la fórmula (1) en donde uno de R1 es H o fórmula (2) y el otro es como en fórmula (3), uno de R2 es H o fórmula (2) y el otro es fórmula (2); CPT es camptotecina, n es 32-3320; m es 0-833; k es 1-216; en donde k, m y n se seleccionan de modo tal que aproximadamente 1% a aproximadamente 15% del compuesto en peso es camptotecina; un agente de estabilización, uno o varios tampones y un tensioactivo; en donde en peso molecular del compuesto va de aproximadamente 10 kD a aproximadamente 500 kD. Reivindicación 5: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde el agente de estabilización está seleccionado del grupo que consiste en sorbitol, manitol, sacarosa, lactosa, glucosa, xilitol, maltosa, hidroxipropil-beta-ciclodextrina, lactitol, dextrosa, glicerina y maltitol. Reivindicación 14: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde uno o varios tampones están seleccionados del grupo que consiste en citrato de sodio, ascorbato, succinato, lactato, ácido cítrico, ácido bórico, bórax, ácido clorhídrico, hidrógeno-fosfato disódico, ácido acético, ácido fórmico, glicina, bicarbonato, ácido tartárico, Tris-glicina, Tris-NaCl, Tris-ácido etilendiamintetraacético (EDTA), Tris-borato-EDTA, tris-acetato-EDTA ("TAE") tampón y solución salina tamponada con Tris, ácido 4-(2-hidroxietil)-1-piperazinetansulfónico ("HEPES"), ácido 3-(N-morfolino)propansulfónico ("MOPS"), ácido piperazin-1, 4-bis (2-etansulfónico) ("PIPES"), ácido 2-(N-morfolino)etansulfónico ("MES"), solución salina tamponada con fosfato ("PBS"), solución salina-citrato de sodio ("SSC"), solución salina-tris-EDTA ("STE") y tris-magnesio. Reivindicación 17: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde el tensioactivo está seleccionado del grupo que consiste en Polysorbate 80, Polysorbate 20, Poloxamer 407, Solutol HS 15, Poloxamer 188, laurilsulfato sódico, etersulfatos, aceites sulfatados, cetrimide BP, cloruro de benzalconio, lecitina, cetromacrogel 1000 BPC y jabones de metales alcalinos de la fórmula RCOOX, donde R = grupo alquilo C10-20 y X = sodio, potasio o amonio. Reivindicación 23: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde la formulación farmacéutica es una solución acuosa muy estable en almacenamiento. Reivindicación 24: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde la formulación es una torta liofilizada apropiada para administración endovenosa después de reconstituir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12138408P | 2008-12-10 | 2008-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR074584A1 true AR074584A1 (es) | 2011-01-26 |
Family
ID=42243068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104793A AR074584A1 (es) | 2008-12-10 | 2009-12-10 | Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables |
Country Status (9)
Country | Link |
---|---|
US (2) | US8491880B2 (es) |
KR (1) | KR20110102420A (es) |
CN (1) | CN102307473A (es) |
AR (1) | AR074584A1 (es) |
CL (1) | CL2009002167A1 (es) |
PA (1) | PA8853201A1 (es) |
PE (1) | PE20100746A1 (es) |
TW (1) | TW201036639A (es) |
WO (1) | WO2010068759A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013528665A (ja) * | 2010-03-26 | 2013-07-11 | メルサナ セラピューティックス, インコーポレイテッド | ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法 |
US20180157397A1 (en) * | 2016-04-08 | 2018-06-07 | Maxx Media Group, LLC | System and Method for Adding Three-Dimensional Images to an Intelligent Virtual Assistant that Appear to Project Forward of or Vertically Above an Electronic Display |
JP6548843B1 (ja) * | 2016-06-03 | 2019-07-24 | ノバサイト インコーポレイテッド | ポリマーリンカーおよびそれらの使用法 |
WO2018075692A2 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
EA201991204A1 (ru) | 2016-12-22 | 2019-12-30 | Университа Дельи Студи Манья Греча Катандзаро | Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43 |
WO2018237262A1 (en) | 2017-06-22 | 2018-12-27 | Mersana Therapeutics, Inc. | METHODS FOR PRODUCING POLYMERIC MATRICES TRANSPORTING MEDICAMENTS, AND PROTEIN-POLYMER-MEDICINE CONJUGATES |
AU2019283314A1 (en) | 2018-06-05 | 2021-01-07 | GammaDelta Therapeutics Limited | BTNL3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4793986A (en) | 1987-02-25 | 1988-12-27 | Johnson Matthey, Inc. | Macromolecular platinum antitumor compounds |
JPH01190636A (ja) | 1988-01-22 | 1989-07-31 | Green Cross Corp:The | 制癌作用物質複合体 |
US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
AU4778893A (en) * | 1992-07-21 | 1994-02-14 | General Hospital Corporation, The | System of drug delivery to the lymphatic tissues |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5612037A (en) * | 1994-07-26 | 1997-03-18 | Connaught Laboratories, Inc. | Influenza virus subunit conjugates |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
WO1996030386A1 (fr) * | 1995-03-31 | 1996-10-03 | Drug Delivery System Institute, Ltd. | Derives d'amidite et derives d'oligonucleotides |
US5811510A (en) * | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
EP0832220A1 (en) | 1995-06-07 | 1998-04-01 | Amgen Inc. | Ob protein compositions and method |
HU226646B1 (en) | 1996-03-12 | 2009-05-28 | Pg Txl Company | Water soluble pharmaceutical compositions containing taxane derivatives |
US5817343A (en) * | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
NZ515999A (en) | 1999-06-18 | 2004-03-26 | Ml Lab Plc | Biologically active materials |
IL131074A0 (en) | 1999-07-23 | 2001-03-19 | Polygene Ltd | A biodegradable polycation composition for delivery of an anionic macromolecule |
US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
EP1206285A2 (en) | 1999-08-09 | 2002-05-22 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
US6822086B1 (en) * | 1999-08-09 | 2004-11-23 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
ES2294026T3 (es) * | 2000-09-06 | 2008-04-01 | Ap Pharma, Inc. | Polimeros degradables de poliacetal. |
ATE410459T1 (de) * | 2002-01-14 | 2008-10-15 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
DE60329126D1 (de) * | 2002-02-20 | 2009-10-15 | Beth Israel Hospital | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
WO2004009774A2 (en) | 2002-07-19 | 2004-01-29 | Amgen Inc. | Protein conjugates with a water-soluble biocompatible, biogradable polymer |
JP4800614B2 (ja) * | 2002-07-19 | 2011-10-26 | ザ ジェネラル ホスピタル コーポレイション | オキシム結合体、およびそれらの形成および使用のための方法 |
MXPA05002444A (es) * | 2002-09-06 | 2005-09-30 | Insert Therapeutics Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
WO2004089311A2 (en) | 2003-03-31 | 2004-10-21 | Vectramed, Inc. | Polymeric drug agents for the treatment of fibrotic disorders |
DE602004032553D1 (de) * | 2003-09-05 | 2011-06-16 | Gen Hospital Corp | Polyacetal-arzneimittelkonjugate als freisetzungssystem |
EP1547580A1 (en) | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Loading of a camptothecin drug into colloidal nanoparticles |
CN101641285B (zh) * | 2007-01-31 | 2012-10-10 | 中央电气工业株式会社 | 碳材料及其制造方法 |
US8399512B2 (en) * | 2007-11-28 | 2013-03-19 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
US20120171118A1 (en) | 2009-06-12 | 2012-07-05 | The General Hospital Corporation | Treatment of meningeal and neural diseases |
-
2009
- 2009-12-10 KR KR1020117015636A patent/KR20110102420A/ko not_active Application Discontinuation
- 2009-12-10 PA PA20098853201A patent/PA8853201A1/es unknown
- 2009-12-10 WO PCT/US2009/067505 patent/WO2010068759A1/en active Application Filing
- 2009-12-10 TW TW098142264A patent/TW201036639A/zh unknown
- 2009-12-10 AR ARP090104793A patent/AR074584A1/es unknown
- 2009-12-10 US US12/635,027 patent/US8491880B2/en not_active Expired - Fee Related
- 2009-12-10 PE PE2009001300A patent/PE20100746A1/es not_active Application Discontinuation
- 2009-12-10 CN CN2009801563966A patent/CN102307473A/zh active Pending
- 2009-12-10 CL CL2009002167A patent/CL2009002167A1/es unknown
-
2013
- 2013-06-18 US US13/920,749 patent/US20140004074A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140004074A1 (en) | 2014-01-02 |
TW201036639A (en) | 2010-10-16 |
PE20100746A1 (es) | 2010-11-04 |
KR20110102420A (ko) | 2011-09-16 |
US8491880B2 (en) | 2013-07-23 |
PA8853201A1 (es) | 2010-07-27 |
CL2009002167A1 (es) | 2010-10-15 |
US20100179181A1 (en) | 2010-07-15 |
CN102307473A (zh) | 2012-01-04 |
WO2010068759A1 (en) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR074584A1 (es) | Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables | |
KR101912709B1 (ko) | 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법 | |
JP2019073563A5 (es) | ||
JP6081173B2 (ja) | 眼科用水性組成物 | |
AR080427A1 (es) | Formulacion liquida para un conjugado de accion prolongada del g-csf | |
CO6400185A2 (es) | Formas de dosificación sólida de bendamustina | |
WO2010070664A4 (en) | Curcuminoids and its metabolites for the application in ocular diseases | |
AR110269A1 (es) | Preparación de nanopartículas de ciclodextrina para la administración de fármacos oftálmicos | |
US11439652B2 (en) | Ophthalmic aqueous composition | |
JP7304282B2 (ja) | カラーコンタクトレンズ用眼科組成物 | |
JP5616618B2 (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
BR112014013890A2 (pt) | formulação em pó seco de derivado de azol para inalação | |
EA037320B1 (ru) | Композиция, содержащая 5-фтор-2'-дезоксируидин-5'-o-[1-нафтил (бензокси-l-аланинил] фосфат, ее применение, способ лечения рака и набор | |
CN101400354A (zh) | 水性组合物 | |
AR079561A1 (es) | Forma de dosificacion farmaceutica oral que contiene un oligosacarido sintetico | |
JP2024061871A (ja) | 眼科組成物 | |
JP5052028B2 (ja) | アシタザノラスト含有組成物 | |
WO2018042363A1 (en) | Pharmaceutical formulations of regadenoson | |
AR086672A1 (es) | Formulaciones de furina recombinante | |
JP2010235508A (ja) | アズレン誘導体含有液剤 | |
JP2007008928A (ja) | アシタザノラスト含有水性組成物 | |
JP2013144672A (ja) | 眼科用水性組成物 | |
CN106236704A (zh) | 一种兼具仿生和靶向功能的莫西沙星滴眼液及其制备方法 | |
JP6876017B2 (ja) | オロパタジン含有水性組成物 | |
KR102288699B1 (ko) | 수성 의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |